Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 9

Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

July 29, 2024

Guillermo Garcia-Manero, MD, Rami Komrokji, MD, Esther Natalie Oliva, MD , Amer Zeidan, MBBS, MHS, Thomas Cluzeau, MD, PhD

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP. 4: Review of the COMMANDS Trial

EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice

EP. 7: Treatment Decision-Making Based on the COMMANDS Trials

EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

Now Viewing

EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP. 10: Safety Profile of Available Frontline Treatments LR-MDS

EP. 11: 1L treatment of lower-risk MDS beyond luspatercept

EP. 12: Sequencing Second-Line Treatments for LR-MDS

EP. 13: Perspectives of IMerge Study

EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Dr. Thomas Cluzeau: Utilization patterns of luspatercept in LR-MDS